Latest news with #SecuritiesExchangeCommission
Yahoo
21-07-2025
- Business
- Yahoo
Explore 290 Genitourinary Licensing Deals - Payment Terms, Trends, and SEC-Filed Contracts
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Genitourinary Collaboration and Licensing Deals 2016-2025" report has been added to offering. Fully revised and updated, the report provides details of 290 genitourinary deals from 2016 to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of genitourinary deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse genitourinary collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Genitourinary Collaboration and Licensing Deals includes: Trends in genitourinary dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of genitourinary deal records covering pharmaceutical and biotechnology The leading genitourinary deals by value Most active genitourinary licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in genitourinary dealmaking2.1. Introduction2.2. Genitourinary partnering over the years2.3. Genitourinary partnering by deal type2.4. Genitourinary partnering by industry sector2.5. Genitourinary partnering by stage of development2.6. Genitourinary partnering by technology type2.7. Genitourinary partnering by therapeutic indicationChapter 3 - Financial deal terms for genitourinary partnering3.1. Introduction3.2. Disclosed financials terms for genitourinary partnering3.3. Genitourinary partnering headline values3.4. Genitourinary deal upfront payments3.5. Genitourinary deal milestone payments3.6. Genitourinary royalty ratesChapter 4 - Leading genitourinary deals and dealmakers4.1. Introduction4.2. Most active in genitourinary partnering4.3. List of most active dealmakers in genitourinary4.4. Top genitourinary deals by valueChapter 5 - Genitourinary contract document directory5.1. Introduction5.2. Genitourinary partnering deals where contract document availableChapter 6 - Genitourinary dealmaking by therapeutic target6.1. Introduction6.2. Deals by genitourinary therapeutic targetDeal directoryDeal directory - Genitourinary deals by company A-Z 2016 to 2025Deal directory - Genitourinary deals by technology type 2016 to 2025Deal type definitions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
21-07-2025
- Business
- Yahoo
Efficiently Identify Immunology Deal Structures and Terms - Upfront, Milestone, Royalties
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2025" report has been added to offering. Fully revised and updated, the report provides details of 909 immunology deals from 2016 to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of immunology deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse immunology collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Immunology Collaboration and Licensing Deals includes: Trends in immunology dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of immunology deal records covering pharmaceutical and biotechnology The leading immunology deals by value Most active immunology licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in immunology dealmaking2.1. Introduction2.2. Immunology partnering over the years2.3. Immunology partnering by deal type2.4. Immunology partnering by industry sector2.5. Immunology partnering by stage of development2.6. Immunology partnering by technology type2.7. Immunology partnering by therapeutic indicationChapter 3 - Financial deal terms for immunology partnering3.1. Introduction3.2. Disclosed financials terms for immunology partnering3.3. Immunology partnering headline values3.4. Immunology deal upfront payments3.5. Immunology deal milestone payments3.6. Immunology royalty ratesChapter 4 - Leading immunology deals and dealmakers4.1. Introduction4.2. Most active in immunology partnering4.3. List of most active dealmakers in immunology4.4. Top immunology deals by valueChapter 5 - Immunology contract document directory5.1. Introduction5.2. Immunology partnering deals where contract document availableChapter 6 - Immunology dealmaking by therapeutic target6.1. Introduction6.2. Deals by immunology therapeutic targetDeal directoryDeal directory - Immunology deals by company A-Z 2016 to 2025Deal directory - Immunology deals by technology type 2016 to 2025Deal type definitions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
09-07-2025
- Business
- Associated Press
Pharmaceuticals and Biotechnology Asset Purchase Agreement Trends Analysis Report 2025 with Directory of High-Value Pharma Deals & Contract Links
DUBLIN--(BUSINESS WIRE)--Jul 9, 2025-- The 'Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2025" report has been added to offering. Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals. Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits: The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners. The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of asset purchase deals. Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal. The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. Analyzing contract agreements allows due diligence of: Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in asset purchase dealmaking 2.1. Introduction 2.2. Types of assets purchased 2.3. Trends in asset purchase deals since 2019 2.3.1. Asset purchase dealmaking by year, 2019-2025 2.3.2. Asset purchase dealmaking by phase of development, 2019-2025 2.3.3. Asset purchase dealmaking by industry sector, 2019-2025 2.3.4. Asset purchase dealmaking by therapy area, 2019-2025 2.3.5. Asset purchase dealmaking by technology type, 2019-2025 2.3.6. Asset purchase dealmaking by most active company, 2019-2025 2.4. Reasons for entering into asset purchase partnering deals 2.4.1. Business assets 2.4.2. Product assets 2.4.3. Royalty assets 2.4.4. Technology assets 2.5. The future of asset purchase deals Chapter 3 - Overview of asset purchase deal structure 3.1. Introduction 3.2. Asset purchase agreement structure Chapter 4 - Leading asset purchase deals 4.1. Introduction 4.2. Top asset purchase deals by value Chapter 5 - Top 25 most active asset purchase dealmakers 5.1. Introduction 5.2. Top 25 most active asset purchase dealmakers Chapter 6 - Asset purchase deals including contracts directory 6.1. Introduction 6.2. Asset purchase deals with contracts 2019-2025 Deal directory For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/09/2025 11:33 AM/DISC: 07/09/2025 11:34 AM
Yahoo
27-06-2025
- Business
- Yahoo
Ripple to drop cross appeal against US SEC in crypto lawsuit, CEO says
(Reuters) -Ripple Labs will withdraw its cross appeal against the U.S. Securities and Exchange Commission in a prolonged legal battle tied to the sale of its XRP tokens, the crypto firm's CEO said on Friday. "We're closing this chapter once and for all," Ripple Labs CEO Brad Garlinghouse said in a post on X, adding that the SEC was also expected to drop its appeal. The move could bring the dispute closer to resolution after years of back-and-forth between the company and the regulator over the token's status as a security. The SEC had sued Ripple for allegedly violating securities laws through the sale of its XRP tokens. In 2023, a judge ruled that XRP sales on public exchanges were legal, but the $728 million of sales to institutional investors broke the rules. Both sides appealed, but later agreed to settle if the judge set aside her injunction and approved lowering the $125 million fine she had imposed on Ripple. However, the judge rejected their request on Thursday. The SEC did not immediately respond to a request for comment.
Yahoo
25-06-2025
- Business
- Yahoo
Gynecology Collaboration and Licensing Agreement Trends Analysis Report 2025
Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "Gynecology Collaboration and Licensing Deals 2016-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gynecology deals entered into by the worlds leading biopharma revised and updated, the report provides details of 150 gynecology deals from 2016 to 2025. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gynecology 3 covers the financial deal terms for deals signed in the gynecology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in gynecology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of gynecology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of gynecology deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in gynecology deal making since addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse gynecology collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Gynecology Collaboration and Licensing Deals includes: Trends in gynecology dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of gynecology deal records covering pharmaceutical and biotechnology The leading gynecology deals by value Most active gynecology licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in gynecology dealmaking2.1. Introduction2.2. Gynecology partnering over the years2.3. Gynecology partnering by deal type2.4. Gynecology partnering by industry sector2.5. Gynecology partnering by stage of development2.6. Gynecology partnering by technology type2.7. Gynecology partnering by therapeutic indicationChapter 3 - Financial deal terms for gynecology partnering3.1. Introduction3.2. Disclosed financials terms for gynecology partnering3.3. Gynecology partnering headline values3.4. Gynecology deal upfront payments3.5. Gynecology deal milestone payments3.6. Gynecology royalty ratesChapter 4 - Leading gynecology deals and dealmakers4.1. Introduction4.2. Most active in gynecology partnering4.3. List of most active dealmakers in gynecology4.4. Top gynecology deals by valueChapter 5 - Gynecology contract document directory5.1. Introduction5.2. Gynecology partnering deals where contract document availableChapter 6 - Gynecology dealmaking by therapeutic target6.1. Introduction6.2. Deals by gynecology therapeutic targetCompanies Featured 23andMe Aarhus University Abbott Laboratories Abbvie Accord Healthcare Acerus Ache AdaptivEndo Advaxis Adynxx AIMA Laboratories AIVF Allakos Allegheny Technologies Altavant Sciences Amag Pharmaceuticals American Dental Association Amring Pharmaceuticals AntibioTx ApolloBio Aptorum Group Ascend Therapeutics Asieris MediTech ASKA Pharmaceuticals Aspen Pharmacare Canada AstraZeneca Auransa Avion Pharmaceuticals Avomeen Bayer Besins Healthcare Bill and Melinda Gates Foundation Biofourmis BioGen Medical BioNano Genomics BioPep BioSyent Pharma BioVaxys Bloom Fertility BMV Medica Brigham and Women's Hospital California Cryobank Cancer Prevention and Research Institute of Texas Celmatix Chinese Academy of Sciences Chugai Pharmaceutical Cicero Diagnostics Co-Diagnostics Cocrystal Pharma Conceptions Reproductive Associates of Colorado Conduit Pharmaceuticals Consortia Health ConTipi Control Flo Medical Coriell Life Sciences Cosette Pharmaceuticals CR Pharma Dare Bioscience Department of Defense Dewpoint Therapeutics Duke University Easton Pharmaceuticals Egalet Embr Labs Emory University EndoCeutics Enzyvant Science Especificos Stendhal Eurofins LifeCodexx European Board and College of Obstetrics and Gynaecology European Wellness Biomedical Group Evidation Health Evofem Biosciences Evotec Evvy Exeltis Expedeon ExSeed Ferring Pharmaceuticals Flo Health Foresee Pharmaceuticals Fujifilm Irvine Scientific Fuji Pharma Gameto Gedeon Richter Genea Biomedx Genetiks Genome Medical Genomic Prediction German Cancer Research Center Gilead Sciences GOG Foundation Good Start Genetics Granata Bio Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals Health Decisions Helix Helix BioPharma Highmark Health Hologic Hope Medicine Hyloris Pharmaceuticals IBSA Group iGenomix Igyxos Illumina Indegene Lifesystems InnerOptic Technology Innovative Health Diagnostics Inovio Pharmaceuticals Inserm Transfert INVO Bioscience Jiangsu Hansoh Pharmaceutical Jiangsu Hengrui Medicine Johns Hopkins University Joylux Karolinska Institute KinoPharma Knight Therapeutics LinKinVax LUCA Science Lumir Lab mAbXience Massachusetts General Hospital Mayne Pharma MD Anderson Cancer Center MDNA Life Sciences Medinova Meitheal Pharmaceuticals Menarini MenoGeniX Merck and Co Merck KGaA Microbix Biosystems MicroGenDX MilanaPharm Millendo Therapeutics Millicent Pharma Milu Labs Mithra Pharmaceuticals Morphic Therapeutic Mundipharma MyBiotics Pharma Mycovia Pharmaceuticals Myovant Sciences Nanjing King-friend Biochemical Pharmaceutical National Human Genome Research Institute National Institute of Child Health and Human Development National Institute on Aging National Institutes of Health Novan NuProbe NX Prenatal ObsEva OmniVision Technologies OncoNano Medicine One Drop Osel Osivax Osteolabs Ovation Oviva Therapeutics OvuSense Palatin Technologies PaxGenBio PDS Biotechnology Pearsanta Pfizer PharmaJet Pharmanest Phase Genomics Photocure ASA Pierre Fabre PolarisQB Predictive Technology Group Procare Health Psyche Systems Purna Pharmaceuticals QIAGEN Radius Health Rebiotix ReproCell Roivant Sciences Royal Philips Electronics Scholar Rock Searchlight Pharma Selexis Sema4 Shandong Yaohua Medical Instrument Shenghuo Medical Skive Hospital Starpharma Statens Serum Institute St George Street Capital Strainprint Technologies Sumitomo Dainippon Pharma Sumitovant Biopharma Sun Pharmaceutical Syneos Health SynteractHCR Systems Oncology Takeda Pharmaceutical Tessa Therapeutics Texas A&M University Theramex TherapeuticsMD Thermo Fisher Scientific TiumBio TMRW Life Sciences Transgene twoXAR Ulisse Biomed University of Antwerp University of Illinois University of Leuven University of Oxford UpScriptHealth Urovant Sciences Vaccibody Valeo Pharma Veritas Viatris VICHY Laboratoires Viramal VirtaMed Vitro Biopharma Woom Xbrane Biopharma Xisle Pharma Ventures Trust For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
